International Stroke Conference 2025  /  Open Q&A Session with the Main Event Late-Breaking Science Trialist(s): Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial (LB20) - at the Neuro Talk Theater (AHA HeadQuarter’s Booth, Booth 528)  /  Q&A Session: Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial (LB20)
Logo

American Heart Association

  8
  0

Final ID:

Q&A Session: Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial (LB20)

  • Awad, Issam  ( UNIV CHICAGO MEDICAL CENTER , Chicago , Illinois , United States )
    • Author Disclosures:
    Issam Awad: DO have relevant financial relationships ; Consultant:Neurelis:Active (exists now) ; Research Funding (PI or named investigator):US DoD:Active (exists now) ; Research Funding (PI or named investigator):NIH/NINDS:Active (exists now) ; Consultant:OVID Therapeutics:Active (exists now)
Meeting Info:

International Stroke Conference 2025

2025

Los Angeles, CA

Session Info:

Open Q&A Session with the Main Event Late-Breaking Science Trialist(s): Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial (LB20) - at the Neuro Talk Theater (AHA HeadQuarter’s Booth, Booth 528)

Thursday, 02/06/2025 , 03:40PM - 04:00PM

ISC Invited Symposium

More abstracts from these authors:
Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations:
A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial

Awad Issam

Treatment of Intracerebral Hemorrhage- Causes and Effects

Awad Issam

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.

   Rate this abstract  (Maximum characters: 500)